Insulet sees 31% revenue jump
By HME News Staff
Updated 10:00 AM CST, Mon November 10, 2025
ACTON, Mass. – Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024. Of that, U.S. Omnipod revenue was $497.1 million and International Omnipod revenue was $202.1 million. “We delivered strong third quarter results, a testament to our team’s exceptional performance and the transformative power of Omnipod 5 for people living with diabetes,” said Ashley McEvoy, president and CEO. “Our continued meaningful engagement with physicians, partners, investors, and our incredible Podder community further reinforces our unique role at the nexus of consumer health, healthcare, and medtech. We’re not just advancing diabetes care—we’re reshaping it.”
Third quarter strategic highlights:
- Integrated Omnipod 5 with Dexcom’s G7 Continuous Glucose Monitor (CGM) sensor in Sweden, Denmark, Finland and Italy
- Secured reimbursement for Omnipod 5 with Dexcom’s G6 and G7 CGM sensors and Abbott's FreeStyle Libre 2 Plus CGM sensor in Norway
- Redeemed remaining $380 million principal of convertible notes
- Partnered with Pantone to launch Omnipod Mango in vibrant new palette
Comments